These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 22153673)

  • 21. [Glucocorticoid-induced osteoporosis].
    Foltyn W; Kos-Kudła B; Marek B; Kajdaniuk D; Głogowska-Szelag J; Siemińska L; Strzelczyk J; Borowska M
    Endokrynol Pol; 2007; 58(2):170-5. PubMed ID: 17578833
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of minodronic acid hydrate in patients with steroid-induced osteoporosis.
    Kitamura N; Shiraiwa H; Inomata H; Nozaki T; Ikumi N; Sugiyama K; Nagasawa Y; Karasawa H; Iwata M; Matsukawa Y; Takei M
    Int J Rheum Dis; 2018 Apr; 21(4):813-820. PubMed ID: 26929019
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Assessment of bone quality. Bone quality of steroid-induced osteoporosis].
    Li M; Saito T; Amizuka N
    Clin Calcium; 2008 Mar; 18(3):328-35. PubMed ID: 18310820
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [An update on glucocorticoid-induced osteoporosis].
    Krasselt M; Baerwald C
    Dtsch Med Wochenschr; 2016 Mar; 141(5):352-7. PubMed ID: 26939107
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prescription for antiresorptive therapy in Mexican patients with rheumatoid arthritis: is it time to reevaluate the strategies for osteoporosis prevention?
    Gamez-Nava JI; Zavaleta-Muñiz SA; Vazquez-Villegas ML; Vega-Lopez A; Rodriguez-Jimenez NA; Olivas-Flores EM; Gonzalez-Montoya NG; Corona-Sanchez EG; Rocha-Muñoz AD; Martinez-Corral ME; Martin-Márquez BT; Vazquez-Del Mercado M; Muñoz-Valle JF; Cardona-Muñoz EG; Celis-De La Rosa A; Cabrera-Pivaral C; Gonzalez-Lopez L
    Rheumatol Int; 2013 Jan; 33(1):145-50. PubMed ID: 22238026
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Skeletal complications of rheumatoid arthritis.
    Heinlen L; Humphrey MB
    Osteoporos Int; 2017 Oct; 28(10):2801-2812. PubMed ID: 28779302
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Treatment with corticosteroids, bone mineral density and risk of fractures].
    Rosa J
    Vnitr Lek; 2003 Jan; 49(1):12-4. PubMed ID: 12666423
    [No Abstract]   [Full Text] [Related]  

  • 28. [Influence of glucocorticoids on bone mineral density in rheumatoid arthritis and seronegative spondyloarthropathies].
    Savickiene A; Baranauskaite A
    Medicina (Kaunas); 2003; 39(5):448-53. PubMed ID: 12794366
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of osteoporosis in rheumatoid arthritis patients.
    Hoes JN; Bultink IE; Lems WF
    Expert Opin Pharmacother; 2015 Mar; 16(4):559-71. PubMed ID: 25626121
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials.
    Amiche MA; Albaum JM; Tadrous M; Pechlivanoglou P; Lévesque LE; Adachi JD; Cadarette SM
    Osteoporos Int; 2016 May; 27(5):1709-18. PubMed ID: 26694595
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety of low- to medium-dose glucocorticoid treatment in rheumatoid arthritis: myths and reality over the years.
    Santiago T; da Silva JA
    Ann N Y Acad Sci; 2014 May; 1318():41-9. PubMed ID: 24814757
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advances in glucocorticoid-induced osteoporosis.
    den Uyl D; Bultink IE; Lems WF
    Curr Rheumatol Rep; 2011 Jun; 13(3):233-40. PubMed ID: 21365209
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glucocorticoid-induced osteoporosis: when and who should we treat?
    Morel G; Biver E; Borg S; Chopin F; Hoppé E; Rajzbaum G
    Joint Bone Spine; 2011 Dec; 78 Suppl 2():S214-7. PubMed ID: 22153674
    [No Abstract]   [Full Text] [Related]  

  • 34. [Preliminary consensus statement on glucocorticoid-induced osteoporosis].
    Scharla SH; Buttgereit F; Dreher R; Felsenberg D; Franck H; Hein G; Lemmel EM; Rau R; Sieper J; Braun J
    Z Rheumatol; 2001 Apr; 60(2):96-9. PubMed ID: 11383055
    [No Abstract]   [Full Text] [Related]  

  • 35. [Pathogenesis and therapy of steroid-induced osteoporosis].
    Braun J; Buttgereit F; Felsenberg D; Sieper J
    Z Rheumatol; 2001 Apr; 60(2):100-3. PubMed ID: 11383042
    [No Abstract]   [Full Text] [Related]  

  • 36. Effects of monthly intramuscular neridronate in rheumatic patients in chronic treatment with low-dose glucocorticoids.
    Benucci M; Saviola G; Baiardi P; Abdi-Ali L; Povino MR; Dolenti S; Campostrini L; Sacco S; Manfredi M; Rossini M
    Clin Exp Rheumatol; 2009; 27(4):567-73. PubMed ID: 19772786
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The effects of glucocorticoid on bone architecture and strength].
    Soen S
    Clin Calcium; 2013 Jul; 23(7):993-9. PubMed ID: 23811587
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapy and prophylaxis of corticosteroid induced osteoporosis.
    Sambrook PN
    Z Rheumatol; 2001 Apr; 60(2):120-2. PubMed ID: 11383049
    [No Abstract]   [Full Text] [Related]  

  • 39. [Pathologic bone fractures in patients treated with corticosteroid preparations for long periods of time].
    Vapra A; Kanmer Kh
    Vopr Revm; 1967; 7(3):80-2. PubMed ID: 5620572
    [No Abstract]   [Full Text] [Related]  

  • 40. Management of glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis: rates and predictors of care in an academic rheumatology practice.
    Solomon DH; Katz JN; Jacobs JP; La Tourette AM; Coblyn J
    Arthritis Rheum; 2002 Dec; 46(12):3136-42. PubMed ID: 12483716
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.